SB-FIX

BIOLOGICAL2 trials

Sponsors

Sangamo Therapeutics

Conditions

Hemophilia BMucopolysaccharidosis IMucopolysaccharidosis II

Phase 1

Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B

TerminatedNCT02695160

Sangamo TherapeuticsHemophilia B

Start: 2016-11-15End: 2021-04-19Updated: 2024-07-19

Unknown Phase

Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX

TerminatedNCT04628871

Sangamo TherapeuticsHemophilia B, Mucopolysaccharidosis I, Mucopolysaccharidosis II

Start: 2020-11-03End: 2026-06-17Updated: 2026-08-13

Related Papers

CRISPR/Cas9: A Potential Life-Saving Tool. What’s next?

Molecular Therapy — Nucleic Acids2017-12-0111 citations